The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

kaerbio.com

Stage

Grant - III | Alive

Total Raised

$1.58M

Last Raised

$300K | 3 yrs ago

About Kaer Biotherapeutics

KAER Biotherapeutics provides new treatments for respiratory diseases through the inhalation of therapeutic aerosols using its proprietary SUPRAER technology. KAER's technology delivers solid-phase fine particle aerosols generated from viscous solutions of high molecular weight drugs and suspensions. It can also be used to deliver high concentrations of sparsely soluble compounds. These inhaled therapeutics are delivered at a preselected size and at high dose rates, minimizing treatment times and improving clinical outcomes. KAER is developing aerosolized surfactant for the treatment of acute respiratory distress and works with pharmaceutical companies to deliver their proprietary agents.

Kaer Biotherapeutics Headquarter Location

926 S. Andreasen Dr. Ste 105

Escondido, California, 92029,

United States

760-480-9400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kaer Biotherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kaer Biotherapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kaer Biotherapeutics Patents

Kaer Biotherapeutics has filed 8 patents.

The 3 most popular patent topics include:

  • Intensive care medicine
  • Respiratory therapy
  • Mechanical ventilation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/6/2018

6/23/2020

Respiratory therapy, Intensive care medicine, Respiratory physiology, Mechanical ventilation, Pulmonology

Grant

Application Date

4/6/2018

Grant Date

6/23/2020

Title

Related Topics

Respiratory therapy, Intensive care medicine, Respiratory physiology, Mechanical ventilation, Pulmonology

Status

Grant

Latest Kaer Biotherapeutics News

Escondido Company’s Respiratory Aid Gets More Federal Funding

Jun 6, 2019

Escondido-based Kaer Biotherapeutics received a $300,000 federal grant to help it develop medical technology that could potentially help premature babies and adults with respiratory problems. Kaer Biotherapeutics’ CEO, Donovan Yeates, presented the invention at the BIO International Convention in Philadelphia on June 3. The company’s technology puts surfactant — a crucial element for lung function — into an aerosol state so it can be sent into the lungs. Kaer Biotherapeutics says its device could be used to treat neonatal respiratory distress syndrome as well as its counterpart in adults. Currently, doctors send liquid surfactant into the lungs via a catheter. Kaer Biotherapeutics describes that procedure as slow and traumatic. The National Heart Lung and Blood Institute of the National Institutes of Health awarded Kaer Biotherapeutics a Small Business Innovation Research (SBIR) phase 1 grant. The company made the news public on May 22. Kaer Biotherapeutics has previously received SBIR grants for phase 1 and phase 2. The company says its Supraer platform technology converts liquids containing active pharmaceutical agents in viscous solutions — such as biologics — into an aerosol form and then delivers them as concentrated, pure, solid-phase aerosols at selected diameters between 1.5 and 5 microns. A micron is one thousandth of a millimeter, the size of some bacteria. By contrast, a strand of human hair can be more than a hundred microns thick. Depending on the size selected, these aerosols are suitable for deposition in the conducting airways or deep lung, the company said. “This latest SBIR award further expands Kaer’s capabilities for providing lifesaving aerosol therapies for critically ill patients with compromised respiratory function, including a system for treating adult acute respiratory distress syndrome (ARDS),” according to a statement issued by Kaer Biotherapeutics. ARDS has a 40% mortality rate with no approved drug treatments. Yeates received his Ph.D. in medical biophysics from the University of Toronto in 1975. He completed his career in academia as a bioengineering professor at the University of Illinois at Chicago. He was also a research physiologist at a Veterans Administration Medical Center in Chicago.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.